Q2 Earnings Estimate for CAPR Issued By HC Wainwright

Capricor Therapeutics Inc (NASDAQ:CAPR) – Equities researchers at HC Wainwright issued their Q2 2025 earnings estimates for Capricor Therapeutics in a research report issued to clients and investors on Thursday, March 20th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will post earnings of ($0.36) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $77.00 target price on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.15. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The firm had revenue of $11.13 million during the quarter, compared to analyst estimates of $9.87 million.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $30.00 price target on shares of Capricor Therapeutics in a research note on Thursday. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Stock Down 10.4 %

Shares of CAPR stock opened at $12.86 on Friday. The company has a 50 day moving average price of $14.06 and a 200-day moving average price of $14.62. Capricor Therapeutics has a 52 week low of $3.52 and a 52 week high of $23.40. The firm has a market capitalization of $584.74 million, a PE ratio of -12.13 and a beta of 4.10.

Institutional Trading of Capricor Therapeutics

Several large investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System grew its position in Capricor Therapeutics by 1,653.0% during the fourth quarter. California State Teachers Retirement System now owns 32,237 shares of the biotechnology company’s stock valued at $445,000 after buying an additional 30,398 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Capricor Therapeutics in the fourth quarter worth approximately $462,000. Voloridge Investment Management LLC bought a new position in shares of Capricor Therapeutics in the fourth quarter worth approximately $1,678,000. Woodline Partners LP bought a new position in shares of Capricor Therapeutics in the fourth quarter worth approximately $8,693,000. Finally, Two Sigma Investments LP boosted its position in shares of Capricor Therapeutics by 223.6% in the fourth quarter. Two Sigma Investments LP now owns 119,047 shares of the biotechnology company’s stock worth $1,643,000 after purchasing an additional 82,254 shares during the period. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.